Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. - Wikidata - wikimedia - TriplyDB

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

http://www.wikidata.org/entity/Q33934312

about

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA HCV Kinetic Models and Their Implications in Drug Development Modelling hepatitis C therapy--predicting effects of treatment Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition.Hepatitis C Virus and Antiviral Drug Resistance Coordination of Hepatitis C Virus Assembly by Distinct Regulatory Regions in Nonstructural Protein 5A NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains.NS2 is dispensable for efficient assembly of hepatitis C virus-like particles in a bipartite trans-encapsidation system.Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.Hepatitis C virus life cycle and lipid metabolism Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase.Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems.Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies.Hepatitis C virus drug resistance-associated substitutions: State of the art summary.Daclatasvir for the treatment of chronic hepatitis C.The safety of daclatasvir for the treatment of hepatitis C.Synergistic Activity of Combined NS5A Inhibitors.Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview.NS5A inhibitors for the treatment of hepatitis C infection.Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.Synthesis and evaluation of novel HCV replication inhibitors.The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.A role for domain I of the hepatitis C virus NS5A protein in virus assembly.A New Age-Structured Multiscale Model of the Hepatitis C Virus Life-Cycle During Infection and Therapy With Direct-Acting Antiviral Agents.Intracellular hepatitis C modeling predicts infection dynamics and viral protein mechanisms.HCV NS5A dimer interface residues regulate HCV replication by controlling its self-interaction, hyperphosphorylation, subcellular localization and interaction with cyclophilin A Current and future targets of antiviral therapy in the hepatitis C virus life cycle

P2860

Q26773321-FD1261AC-307D-4623-8C48-2FF7E0CF3C86 Q26800446-9D559D13-02DA-4929-80EF-1C32D3318065 Q26801602-9C9AB732-14A8-4D6F-97F1-4C79FF1D355B Q26864673-4207BB03-C906-4AB6-B3AD-10F58959A84B Q27335920-AABC48F7-D9AA-4B81-B68A-DE8A09373A0D Q28067295-ED3EF52A-8425-4960-91CC-BEBB72FC01AD Q28551959-F66BFEF5-CC70-4211-8AFA-2D840BCF3BD9 Q33778857-5008993D-154C-4078-BC21-9E50A732F994 Q34366406-194B6E86-4C50-4EBA-9B55-433784013493 Q34580799-D1A309B7-1EC5-4BEF-BB6F-31697036B06A Q34792436-100B4946-55E6-4F9F-8DF1-920E48B11340 Q35070501-4B850937-4938-41E2-9F9D-6BCB444A51AE Q35385005-01C75AE8-1793-40FB-83BE-882F256D5E72 Q35449696-F1BAAC53-836A-42A5-872A-30F94D66E139 Q35542987-96FA8C7B-E411-4176-A3BA-CA79E3BC086A Q35607835-0406E21F-94EF-4592-B535-D579C82C35E3 Q35746343-FF8AB792-12D0-41EC-82CD-7A8B9671CC76 Q35774186-88EE75A6-5D89-4CA5-BCFB-7D253936D29C Q36744202-78EF149B-2D5C-4E38-9F0F-59FD53618F94 Q36807370-36B1472E-7638-4487-9AD0-122F7C47FE60 Q37148014-9CD78909-B87E-48E9-B069-DD87732923A1 Q37721750-E134742B-E765-4DD6-AE8D-B1F0AE98BCD9 Q38533619-10F6F945-6A5B-4079-B982-EAA4285B16AD Q38628237-F1A6C136-B34A-4152-ADAB-A7F6229456E6 Q38634221-0FCC89E9-D712-4A12-A9FE-A886814784FB Q38741143-9FCDFCAF-B892-4DA3-8AC4-58FDA0A78830 Q38893104-71400F88-7F88-424E-B56A-35FD4A3D9A97 Q38903369-5BCE39E8-EFBD-4E9D-93E2-C47F844E4B96 Q38956355-C8959DD4-E88B-441F-BDB7-548A7B71B88C Q39015799-EBA60253-B960-453E-BF12-1295CEB47E94 Q39031350-DEB92FBE-CE53-4775-94EA-079306351F9F Q40239514-63FAC8F8-EEAD-4EF3-A41C-D3414830249D Q40292258-F7AC6D36-F6A4-4B1B-A534-E2203063DDA7 Q40773451-9A0BB6EB-CC4F-4E41-9AED-651A83A76613 Q42192444-9F1F1BE5-DA5A-49E8-BCED-E81693BBC20E Q47551049-16869603-2A6E-4EEC-BE36-571181A1A739 Q52579185-2D8556CE-70CC-45B0-B348-67F11535F92B Q52644040-7BDCFEE0-D0F5-459C-9E87-E66506B5D873 Q56396163-A00117DF-14B4-4D40-B613-BE7924453000 Q57071775-DD10E1A3-DBEC-4BA2-B870-5DBED333B499

P2860

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

http://www.wikidata.org/entity/Q33934312

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Kinetic analyses reveal potent ...... s assembly by NS5A inhibitors.

@ast

Kinetic analyses reveal potent ...... s assembly by NS5A inhibitors.

@en

type

label

Kinetic analyses reveal potent ...... s assembly by NS5A inhibitors.

@ast

Kinetic analyses reveal potent ...... s assembly by NS5A inhibitors.

@en

prefLabel

Kinetic analyses reveal potent ...... s assembly by NS5A inhibitors.

@ast

Kinetic analyses reveal potent ...... s assembly by NS5A inhibitors.

@en

P1433

Q33934312-0D23DBD2-B053-4369-A6E4-989F39BFFC76

P1476

Q33934312-D77ADF91-5DA9-4401-8E15-786DC205C0B6

P2093

Q33934312-3C915081-9311-4285-9477-882C208A824B

Q33934312-5F52D8B5-0D73-4BAF-9EBA-21569B9207A9

Q33934312-63C527EC-4ACA-4396-984B-ADAD55E323FB

Q33934312-7FE4B3EC-1219-49C1-96F9-152C8E321655

Q33934312-86E23490-A8C0-455B-A1E2-EA6FE63336A6

Q33934312-936C4769-17E4-48EC-A9BC-3134C431D963

Q33934312-C2FAEEC0-56AE-40EE-8FE8-1E9777491D4A

P2860

Q33934312-0C62031B-CE8B-4AD9-9EB3-344BA1C54228

Q33934312-11B7117C-707E-40A9-948C-AE6D363C88E9

Q33934312-144ED819-B1AA-461D-95D0-7DC9D7841A17

Q33934312-19403047-6755-4CDD-A9E1-6ED06EB6173D

Q33934312-201FD83F-7DFC-4187-A368-D2A7A51C2C3C

Q33934312-2477AF17-A26E-4EC6-A0AB-FA71786F4B4D

Q33934312-24E71B7F-2253-40EF-B50C-3C9986BF1D4B

Q33934312-24F70984-7998-43BA-9F01-E6AA85C1458C

Q33934312-26761B87-00C5-4179-8335-C1FC70057B63

Q33934312-2B696547-6648-40B3-A46D-48B173F01503

P304

Q33934312-973D9C0E-5076-4AC2-89E9-995D5B62C228

P31

Q33934312-A97ECF7E-1978-41F2-8326-08FD70628219

P356

Q33934312-4B1256A4-D1AE-4C4F-B236-974264CADB05

P407

Q33934312-74685D61-51F1-4B41-98F7-D82B6777A90F

P433

Q33934312-18A130A6-AE84-4AB4-9B39-5D9D8D2C51F3

P478

Q33934312-20A4633D-1B7D-4BFD-B869-1F4540A68CF3

P50

Q33934312-9C7524F2-01F1-483A-84DE-0C57F1D87FD7

Q33934312-C08EA89C-E24E-4FB8-BF77-BE604C24A339

Q33934312-E36CA07B-AEB2-4D57-9033-2C3E6D90D9A1

Q33934312-E5610F33-C287-41CA-A416-9AE50F26BCFA

P577

Q33934312-FCECB970-B621-48AF-B7A3-ED635244BD7E

P5875

Q33934312-9B88EE59-B623-42E2-B683-C847CA0908D0

P698

Q33934312-CA8439B4-80A0-44D4-A4C9-ABCE8E1B7563

P932

Q33934312-17E6BCD7-49BF-42CD-BE11-51F00A818BE1

P356

J.GASTRO.2014.04.021

P1433

Gastroenterology

P1476

Kinetic analyses reveal potent ...... us assembly by NS5A inhibitors

@en

P2093

Anita Y Howe

http://www.w3.org/2001/XMLSchema#string

Ernest Asante-Appiah

http://www.w3.org/2001/XMLSchema#string

Paul Ingravallo

http://www.w3.org/2001/XMLSchema#string

Petra Neddermann

http://www.w3.org/2001/XMLSchema#string

Sara Williford

http://www.w3.org/2001/XMLSchema#string

Stanley M Lemon

http://www.w3.org/2001/XMLSchema#string

Takahiro Masaki

http://www.w3.org/2001/XMLSchema#string

P2860

The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A

Emerging therapies for the treatment of hepatitis C

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein

Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly

NS3 Helicase Domains Involved in Infectious Intracellular Hepatitis C Virus Particle Assembly

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

A dynamic view of hepatitis C virus replication complexes

Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees

Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication

P304

453-62.e7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2014.04.021

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

147

http://www.w3.org/2001/XMLSchema#string

P50

Raffaele De Francesco

David R. McGivern

P577

2014-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261919088

http://www.w3.org/2001/XMLSchema#string

P698

24768676

http://www.w3.org/2001/XMLSchema#string

P932

4107048

http://www.w3.org/2001/XMLSchema#string